@article{7d4ae0d58ded4a06bc51fc18c2e4273a,
title = "Presymptomatic testing and confidentiality in the age of the electronic medical record",
abstract = "Objective: Recent introduction of a commercial electronic medical record (EMR) system at the authors{\textquoteright} institution raised a number of questions about documenting visits for pre-symptomatic testing for Huntington{\textquoteright}s disease (HD). Specifi-cally, adoption of the EMR potentially compromised patient confidentiality and the personal delivery of test results, both of which are strongly recommended by professional consensus and lay organizations. Methods: The authors surveyed peer institutions about their experience with EMR systems in the setting of presymptomatic testing for HD. Results: Answers from 10 well-known HD specialty centers demonstrated a wide variety of approaches to managing these concerns. The responses did not clarify how to resolve the collision between the virtues of a shared medical record and the goal of patient control of sensitive medical information. Conclusions: These results demonstrate that important issues remain unresolved. The authors propose that medical record systems must adapt to and respect the patient{\textquoteright}s desires for confidentiality and allow people undergoing presymptomatic testing to restrict access to this sensitive information.",
author = "Black, {Kevin J.} and Barton, {Stacey K.} and Perlmutter, {Joel S.}",
note = "Funding Information: Supported in part by the American Parkinson Disease Association (APDA) Center for Advanced Parkinson Disease Research at Washington University School of Medicine, the Barnes-Jewish Hospital Foundation (Elliot Stein Family Fund and Parkinson Disease Research Fund), the Cure Huntington{\textquoteright}s Disease Initiative Foundation, the Greater St. Louis Chapter of the APDA, the Huntington{\textquoteright}s Disease Society of America (HDSA), and the HDSA Center of Excellence at Washington University in St. Louis. Funding Information: Supported in part by the American Parkinson Disease Association (APDA) Center for Advanced Parkinson Disease Research at Washington University School of Medicine, the Barnes-Jewish Hospital Foundation (Elliot Stein Family Fund and Parkinson Disease Research Fund), the Cure Huntington?s Disease Initiative Foundation, the Greater St. Louis Chapter of the APDA, the Huntington?s Disease Society of America (HDSA), and the HDSA Center of Excellence at Washington University in St. Louis. The funders had no role in the study design, data collection, analysis, or decision to publish this article. Dr. Black has served as a consultant to Acadia Pharmaceuticals; he has received research grant support from Acadia Pharmaceuticals, Emalex Biosciences, and Neurocrine Biosciences; and he has served on the speaker?s bureaus of Acadia Pharmaceuticals and Teva Pharmaceuticals. Funding Information: Dr. Black has served as a consultant to Acadia Pharmaceuticals; he has received research grant support from Acadia Pharmaceuticals, Emalex Biosciences, and Neurocrine Biosciences; and he has served on the speaker{\textquoteright}s bureaus of Acadia Pharmaceuticals and Teva Pharmaceuticals. The other authors report no financial relationships with commercial interests. Publisher Copyright: {\textcopyright} 2021, American Psychiatric Association. All rights reserved.",
year = "2021",
month = jan,
doi = "10.1176/appi.neuropsych.20030068",
language = "English",
volume = "33",
pages = "80--83",
journal = "Journal of Neuropsychiatry and Clinical Neurosciences",
issn = "0895-0172",
number = "1",
}